Skip to main content

Table 6 Base-case parameters and values used in sensitivity analysis

From: Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective

  Base-case Sensitivity analysis
Prevalence: ±30%
  12.7 per 100,000 6.4 per 100,000 19.1 per 100,000
Patients treated with prophylaxis: ±25%
  55% 41% 69%
rFVIIIFc uptake rate: −50%; + 25%
 Year 1 10% 5% 12.5%
 Year 2 15% 7.5% 18.8%
 Year 3 20% 10% 25%
rFVIIIFc dosage (IU/Kg): ±30%
 Paediatric patients 44.1 30.8 57.3
 Adult patients 38.95 27.3 50.6
Dosage of conventional products (IU/Kg): ±30%
 Paediatric patients 33.8 23.7 43.9
 Adult patients 43 30.1 55.9
Products cost (Euro/IU): −15% rFVIIIFc;– 15% conventional products
 rFVIIIFc 0.72 0.61 0.72
 Advate® 0.65 0.65 0.55
 Kogenate® 0.69 0.69 0.59
 Refacto® 0.69 0.69 0.59
 Helixate® 0.69 0.69 0.59
 Recombinate® 0.60 0.60 0.51
 Plasma-derived product 0.60 0.60 0.51
\